2028 Licensing Pharmaceuticals Treatment 
Drug Discovery World
SEPTEMBER 26, 2022
It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. According to MarketWatch, the drug repurposing sector was thought to be worth $25,280 in 2021 and is expected to grow to $30,620 million by 2028 with a CAGR of 2.8%. Benefits and barriers .
The Pharma Data
JANUARY 9, 2021
This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. Other 2021 Assumptions. FOOTNOTES. (1) FOOTNOTES. (1)
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Codon
SEPTEMBER 29, 2024
2028 Over the next year, the scientific community ferociously interrogated the model. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. The single remaining pharmaceutical company was thus nationalized, data was collected, and the trained model deployed in full force.
The Pharma Data
NOVEMBER 4, 2020
REDUCE-IT RENAL results presented in October 2020 showed, through prespecified and post hoc subgroup analyses, that patients in the REDUCE-IT study who had compromised renal function at baseline prior to treatment with VASCEPA or placebo, experienced higher rates of cardiovascular events than the overall population studied in REDUCE-IT.
The Pharma Data
SEPTEMBER 15, 2020
27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer announced several key advances in its efforts to protect humankind from the COVID-19 pandemic and prepare the pharmaceutical industry to better respond to future global health crises.
Expert insights. Personalized for you.
130 
Let's personalize your content